CN106164090A - TRAIL穿膜肽样突变体MuR6、制备方法及应用 - Google Patents

TRAIL穿膜肽样突变体MuR6、制备方法及应用 Download PDF

Info

Publication number
CN106164090A
CN106164090A CN201580000087.5A CN201580000087A CN106164090A CN 106164090 A CN106164090 A CN 106164090A CN 201580000087 A CN201580000087 A CN 201580000087A CN 106164090 A CN106164090 A CN 106164090A
Authority
CN
China
Prior art keywords
mutant
mur6
preparation
trail
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201580000087.5A
Other languages
English (en)
Other versions
CN106164090B (zh
Inventor
陈守春
闫娟
徐琦
黄先洲
魏利佳
胡海洋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Huachuang Biotechnology Co ltd
Original Assignee
Chengdu Hua Chuan Bioisystech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Hua Chuan Bioisystech Co Ltd filed Critical Chengdu Hua Chuan Bioisystech Co Ltd
Publication of CN106164090A publication Critical patent/CN106164090A/zh
Application granted granted Critical
Publication of CN106164090B publication Critical patent/CN106164090B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

提供了一种TRAIL穿膜肽样突变体MuR6、制备方法及应用，所述突变体是通过选择性地将TRAIL野生型蛋白胞膜外段第114～119位氨基酸编码序列由VRERGP改造为RRRRRR，成为包含穿膜样肽结构的蛋白。所述TRAIL突变体可用于治疗肿瘤。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201580000087.5A 2015-03-02 2015-03-02 TRAIL穿膜肽样突变体MuR6、制备方法及应用 Expired - Fee Related CN106164090B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/073524 WO2016138625A1 (zh) 2015-03-02 2015-03-02 TRAIL穿膜肽样突变体MuR6、制备方法及应用

Publications (2)

Publication Number Publication Date
CN106164090A true CN106164090A (zh) 2016-11-23
CN106164090B CN106164090B (zh) 2019-07-23

Family

ID=56849080

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580000087.5A Expired - Fee Related CN106164090B (zh) 2015-03-02 2015-03-02 TRAIL穿膜肽样突变体MuR6、制备方法及应用

Country Status (4)

Country Link
US (1) US10000541B2 (zh)
EP (1) EP3266797B1 (zh)
CN (1) CN106164090B (zh)
WO (1) WO2016138625A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108026181A (zh) * 2015-10-22 2018-05-11 成都华创生物技术有限公司 一种TRAIL双靶点突变蛋白MuR6S4TR、其制备方法及其应用
CN109125709A (zh) * 2018-08-23 2019-01-04 成都华创生物技术有限公司 Trail突变体在制备治疗痤疮药物中的应用及一种制剂

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019000327A1 (zh) * 2017-06-29 2019-01-03 成都华创生物技术有限公司 一种trail类蛋白持续抑制肿瘤细胞生长的给药方法
CN110760478A (zh) * 2018-07-27 2020-02-07 复旦大学 一种抗肿瘤巨噬细胞生物反应器系统及其制备方法
CN110511273B (zh) * 2019-07-12 2021-06-01 福州市皮肤病防治院 一种细胞穿膜多肽的制备方法及其应用
US20220306768A1 (en) * 2021-03-24 2022-09-29 City Of Hope Redirecting death-inducing signal complex (disc) by modifying death receptor agonist to induce cell death for cancer treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1958794A (zh) * 2005-11-03 2007-05-09 成都地奥制药集团有限公司 人肿瘤坏死因子相关凋亡诱导配体突变体编码cDNA及制备方法和应用
US20110300629A1 (en) * 2010-06-08 2011-12-08 Washington University TRAIL trimers, methods and uses therefor
CN103555729A (zh) * 2013-10-14 2014-02-05 成都华创生物技术有限公司 一种改造的trail基因序列、表达方法及应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL391627A1 (pl) * 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1958794A (zh) * 2005-11-03 2007-05-09 成都地奥制药集团有限公司 人肿瘤坏死因子相关凋亡诱导配体突变体编码cDNA及制备方法和应用
US20110300629A1 (en) * 2010-06-08 2011-12-08 Washington University TRAIL trimers, methods and uses therefor
CN103555729A (zh) * 2013-10-14 2014-02-05 成都华创生物技术有限公司 一种改造的trail基因序列、表达方法及应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108026181A (zh) * 2015-10-22 2018-05-11 成都华创生物技术有限公司 一种TRAIL双靶点突变蛋白MuR6S4TR、其制备方法及其应用
CN109125709A (zh) * 2018-08-23 2019-01-04 成都华创生物技术有限公司 Trail突变体在制备治疗痤疮药物中的应用及一种制剂

Also Published As

Publication number Publication date
WO2016138625A1 (zh) 2016-09-09
EP3266797A1 (en) 2018-01-10
US20170247424A1 (en) 2017-08-31
EP3266797B1 (en) 2018-12-05
US10000541B2 (en) 2018-06-19
CN106164090B (zh) 2019-07-23
EP3266797A4 (en) 2018-02-07

Similar Documents

Publication Publication Date Title
CN106164090A (zh) TRAIL穿膜肽样突变体MuR6、制备方法及应用
PH12018501882A1 (en) Binding proteins and methods of use thereof
WO2018191502A3 (en) Anti-cd137 antibodies and methods of use thereof
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
PH12019500122A1 (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
SA518390954B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18
WO2015112886A3 (en) Binding proteins and methods of use thereof
WO2014113490A3 (en) Immunogenic wt-1 peptides and methods of use thereof
MX2018009011A (es) Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
MY156286A (en) Human il-23 antigen binding proteins
WO2017025179A8 (en) A transglutamine tag for efficient site-specific bioconjugation
WO2015112558A3 (en) Peptides, devices, and methods for the detection of anaplasma antibodies
EP3103471A3 (en) Acinetobacter baumanii antigens and the uses thereof
EP4269562A3 (en) Antigen binding molecules and methods of use thereof
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
WO2015107363A3 (en) Mycobacterial antigen composition
WO2020163743A8 (en) Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
WO2016020882A3 (en) Angiopoetin-like 4 (angptl4) antibodies and methods of use
WO2017040329A3 (en) Peptides binding to bfl-1
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
WO2018172259A3 (en) IMPROVED LI VACCINE ADJUVANT
CN106132986A (zh) TRAIL穿膜肽样突变体MuR5、制备方法及应用
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
MX2023003934A (es) Antigenos de consenso de filovirus, construcciones de acido nucleico y vacunas realizadas a partir de estos, y metodos para utilizarlos.
WO2018081350A8 (en) SIGNAL POLYPEPTIDE FOR ENHANCED PROTEIN SECRETION

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220318

Address after: No. 688, Tianshengqiao Avenue, yongyang street, Lishui District, Nanjing City, Jiangsu Province, 211299

Patentee after: Nanjing Huachuang Biotechnology Co.,Ltd.

Address before: 610041 room 409, floor 4, building 12, No. 88, Keyuan South Road, high tech Zone, Chengdu, Sichuan

Patentee before: CHENGDU HUACHUANG BIOTECHNOLOGY Co.,Ltd.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190723